Kanaph Therapeutics Inc.

As of June 30, 2026, Kanaph Therapeutics Inc. carries a market capitalization of 196.66B, placing it among publicly traded companies globally. Its enterprise value stands at 151.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kanaph Therapeutics Inc. has 13.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 28.93, and the price-to-book ratio stands at 4.25.

These figures are as of June 30, 2026. The EV/Sales ratio of 26.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 151.66B versus a market cap of 196.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kanaph Therapeutics Inc. maintains a current ratio of 36.31, meaning it holds 36.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.32, indicating conservative leverage, while an interest coverage ratio of -8.58 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 245.04M in revenue per employee across its workforce of 23.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 23, 2026.

Over the twelve months ended June 30, 2026, Kanaph Therapeutics Inc. generated 5.64B in revenue and converted that into -41.13B in net income, yielding earnings per share of -3,789.00. EBITDA reached -9.44B, while operating income came in at -10.22B.

As of June 30, 2026, Kanaph Therapeutics Inc. holds 45.14B in cash and equivalents against 147.30M in total debt, resulting in a net debt position of -10.14B. Total book value stands at 46.32B, with working capital of 45.76B providing operational flexibility.

Kanaph Therapeutics Inc. produced -10.72B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -53.58M in capital expenditures, free cash flow totaled -10.77B - equivalent to -992.33 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -181.31 and net profit margin of -729.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -21.34, meaning Kanaph Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Kanaph Therapeutics Inc. has an Altman Z-Score of 55.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.